ClinicalTrials.Veeva

Menu

Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus

Case Western Reserve University logo

Case Western Reserve University

Status

Completed

Conditions

Nystagmus

Treatments

Drug: memantine
Drug: gabapentin

Study type

Interventional

Funder types

Other

Identifiers

NCT00928954
NIHR01EY06717 (Other Identifier)
NIH R01 EYO6717 (Other Grant/Funding Number)

Details and patient eligibility

About

Involuntary oscillations of the eyes (nystagmus) impairs vision so that affected patients, who have neurological disorders such as Multiple Sclerosis (MS) , cannot read or watch TV. Two medicines have been reported to suppress nystagmus and improve vision in such patients: gabapentin and memantine. The investigators set out to test which of these two drug was more effective by carrying out a double-blind cross-over study. In this way, we could determine which drug worked best in each patient.

Full description

The study entails careful measurements of visual acuity and precise measurements of eye movements, using a contact lens device (magnetic search coil method). In this way, it is possible to make objective and reliable measurements of the effect of each drug, which are unbiased by the investigator or the patient.

Enrollment

10 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult (18 years or older) males or females with acquired nystagmus that is degrading their vision

Exclusion criteria

  • Pregnant women
  • Individuals who cannot describe their visual symptoms, cooperate with testing, or give informed consent
  • Individuals with intolerance of gabapentin or memantine

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Triple Blind

10 participants in 2 patient groups

Gabapentin
Active Comparator group
Description:
Increasing dose to 300 mg four times per day (total of 1200 mg/day)
Treatment:
Drug: gabapentin
Memantine
Active Comparator group
Description:
Increasing dose over two weeks to 20 mg twice/day (total of 40 mg/day).
Treatment:
Drug: memantine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems